Risk assessment for vitamin D

John N. Hathcock, Andrew Shao, Reinhold Vieth, Robert Heaney

Research output: Contribution to journalReview article

606 Citations (Scopus)

Abstract

The objective of this review was to apply the risk assessment methodology used by the Food and Nutrition Board (FNB) to derive a revised safe Tolerable Upper Intake Level (UL) for vitamin D. New data continue to emerge regarding the health benefits of vitamin D beyond its role in bone. The intakes associated with those benefits suggest a need for levels of supplementation, food fortification, or both that are higher than current levels. A prevailing concern exists, however, regarding the potential for toxicity related to excessive vitaminDintakes. The UL established by the FNB for vitaminD(50 μg, or 2000 IU) is not based on current evidence and is viewed by many as being too restrictive, thus curtailing research, commercial development, and optimization of nutritional policy. Human clinical trial data published subsequent to the establishment of the FNB vitamin D UL published in 1997 support a significantly higher UL. We present a risk assessment based on relevant, well-designed human clinical trials of vitamin D. Collectively, the absence of toxicity in trials conducted in healthy adults that used vitamin D dose ≥250 μg/d (10 000 IU vitamin D3) supports the confident selection of this value as the UL.

Original languageEnglish
Pages (from-to)6-18
Number of pages13
JournalAmerican Journal of Clinical Nutrition
Volume85
Issue number1
StatePublished - Jan 1 2007

Fingerprint

vitamin D
Vitamin D
risk assessment
nutrition
Food
clinical trials
Tolerable Upper Intake Level
Clinical Trials
risk assessment process
toxicity
nutrition policy
food fortification
food service
cholecalciferol
Cholecalciferol
Insurance Benefits
Dietary Supplements
bones
Bone and Bones
dosage

All Science Journal Classification (ASJC) codes

  • Food Science
  • Medicine (miscellaneous)

Cite this

Hathcock, J. N., Shao, A., Vieth, R., & Heaney, R. (2007). Risk assessment for vitamin D. American Journal of Clinical Nutrition, 85(1), 6-18.

Risk assessment for vitamin D. / Hathcock, John N.; Shao, Andrew; Vieth, Reinhold; Heaney, Robert.

In: American Journal of Clinical Nutrition, Vol. 85, No. 1, 01.01.2007, p. 6-18.

Research output: Contribution to journalReview article

Hathcock, JN, Shao, A, Vieth, R & Heaney, R 2007, 'Risk assessment for vitamin D', American Journal of Clinical Nutrition, vol. 85, no. 1, pp. 6-18.
Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. American Journal of Clinical Nutrition. 2007 Jan 1;85(1):6-18.
Hathcock, John N. ; Shao, Andrew ; Vieth, Reinhold ; Heaney, Robert. / Risk assessment for vitamin D. In: American Journal of Clinical Nutrition. 2007 ; Vol. 85, No. 1. pp. 6-18.
@article{5c398b54f52744a28e69f037438daab9,
title = "Risk assessment for vitamin D",
abstract = "The objective of this review was to apply the risk assessment methodology used by the Food and Nutrition Board (FNB) to derive a revised safe Tolerable Upper Intake Level (UL) for vitamin D. New data continue to emerge regarding the health benefits of vitamin D beyond its role in bone. The intakes associated with those benefits suggest a need for levels of supplementation, food fortification, or both that are higher than current levels. A prevailing concern exists, however, regarding the potential for toxicity related to excessive vitaminDintakes. The UL established by the FNB for vitaminD(50 μg, or 2000 IU) is not based on current evidence and is viewed by many as being too restrictive, thus curtailing research, commercial development, and optimization of nutritional policy. Human clinical trial data published subsequent to the establishment of the FNB vitamin D UL published in 1997 support a significantly higher UL. We present a risk assessment based on relevant, well-designed human clinical trials of vitamin D. Collectively, the absence of toxicity in trials conducted in healthy adults that used vitamin D dose ≥250 μg/d (10 000 IU vitamin D3) supports the confident selection of this value as the UL.",
author = "Hathcock, {John N.} and Andrew Shao and Reinhold Vieth and Robert Heaney",
year = "2007",
month = "1",
day = "1",
language = "English",
volume = "85",
pages = "6--18",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "1",

}

TY - JOUR

T1 - Risk assessment for vitamin D

AU - Hathcock, John N.

AU - Shao, Andrew

AU - Vieth, Reinhold

AU - Heaney, Robert

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The objective of this review was to apply the risk assessment methodology used by the Food and Nutrition Board (FNB) to derive a revised safe Tolerable Upper Intake Level (UL) for vitamin D. New data continue to emerge regarding the health benefits of vitamin D beyond its role in bone. The intakes associated with those benefits suggest a need for levels of supplementation, food fortification, or both that are higher than current levels. A prevailing concern exists, however, regarding the potential for toxicity related to excessive vitaminDintakes. The UL established by the FNB for vitaminD(50 μg, or 2000 IU) is not based on current evidence and is viewed by many as being too restrictive, thus curtailing research, commercial development, and optimization of nutritional policy. Human clinical trial data published subsequent to the establishment of the FNB vitamin D UL published in 1997 support a significantly higher UL. We present a risk assessment based on relevant, well-designed human clinical trials of vitamin D. Collectively, the absence of toxicity in trials conducted in healthy adults that used vitamin D dose ≥250 μg/d (10 000 IU vitamin D3) supports the confident selection of this value as the UL.

AB - The objective of this review was to apply the risk assessment methodology used by the Food and Nutrition Board (FNB) to derive a revised safe Tolerable Upper Intake Level (UL) for vitamin D. New data continue to emerge regarding the health benefits of vitamin D beyond its role in bone. The intakes associated with those benefits suggest a need for levels of supplementation, food fortification, or both that are higher than current levels. A prevailing concern exists, however, regarding the potential for toxicity related to excessive vitaminDintakes. The UL established by the FNB for vitaminD(50 μg, or 2000 IU) is not based on current evidence and is viewed by many as being too restrictive, thus curtailing research, commercial development, and optimization of nutritional policy. Human clinical trial data published subsequent to the establishment of the FNB vitamin D UL published in 1997 support a significantly higher UL. We present a risk assessment based on relevant, well-designed human clinical trials of vitamin D. Collectively, the absence of toxicity in trials conducted in healthy adults that used vitamin D dose ≥250 μg/d (10 000 IU vitamin D3) supports the confident selection of this value as the UL.

UR - http://www.scopus.com/inward/record.url?scp=33846047531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846047531&partnerID=8YFLogxK

M3 - Review article

VL - 85

SP - 6

EP - 18

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

SN - 0002-9165

IS - 1

ER -